This global pharmaceutical company, established in 1970, prioritizes research and development of innovative healthcare products. With a focus on oncology, metabolic diseases, autoimmune diseases, and cardiovascular diseases, they have developed 14 in-house innovative products and partnered with other companies to bring 2 more to market. They boast over 5,000 R&D personnel across fourteen global centers and subsidiaries in North America, the EU, Australia, and Japan. Their commitment to innovation is evidenced by over 90 innovative drug candidates in development and nearly 20 undergoing clinical trials worldwide. The company holds numerous patents granted in key regions like the US, EU, and Japan, demonstrating their strong intellectual property portfolio. They manufacture products that meet or exceed European Union and US Pharmacopoeia standards, exporting to markets including the US, EU, and Japan.

Established in 2018, this manufacturer specializes in oncology, anti-cancer, cytotoxic, critical-care, life-saving, and general injectables, as well as oral solids like tablets and capsules. As a CTD dossier owner and manufacturer, it exports products to over 30 countries across Asia, Africa, LATAM, CIS, MENA, and Europe. Operating under WHO-GMP and PIC/S certifications, the GMP manufacturer maintains advanced production lines for liquid injectables, lyophilized injectables, pre-filled syringes, tablets, and capsules. As a CTD dossier owner and manufacturer, it upholds stringent quality standards and regulatory compliance